SEC Filing Summary: PerkinElmer, Inc. (Form 8-K)
Business Context and Reporting Period
Company: PerkinElmer, Inc. (Note: The input metadata references "REVVITY, INC.", but the filing text identifies the registrant as PerkinElmer, Inc.)
Date of Report: October 25, 2011
Reporting Period: Current Report for events occurring on October 25, 2011.
This filing reports the entry into a material definitive agreement regarding a public debt offering and the termination of a bridge loan facility to fund the acquisition of Caliper Life Sciences, Inc.
Key Financial Metrics and Capital Structure
- Debt Issuance: $500 million aggregate principal amount of 5.00% Senior Notes due 2021.
- Net Proceeds: Approximately $490.6 million (after underwriting discounts and estimated offering expenses).
- Interest Rate: 5.00% per annum, payable semi-annually (May 15 and November 15).
- Maturity Date: November 15, 2021.
- Acquisition Funding: Proceeds intended to fund part of the cash consideration for the acquisition of Caliper Life Sciences, Inc. (Estimated aggregate purchase price: ~$600 million net of acquired cash).
- Bridge Facility: A previously committed $400 million unsecured 364-day bridge loan facility was terminated effective October 25, 2011, as commitments were reduced by the gross proceeds of the Notes.
Note: The filing does not provide specific values for revenue, profit, operating cash flow, or existing debt levels outside of the new issuance and terminated facility.
Material Changes and Transaction Details
- Debt Structure: The Notes are general unsecured obligations, effectively subordinated to secured indebtedness and structurally subordinated to subsidiary liabilities. They rank equal with other unsecured unsubordinated indebtedness.
- Redemption Terms:
- Before August 15, 2021: Redeemable at the greater of 100% of principal or the present value of remaining payments discounted at the Treasury Rate plus 45 basis points.
- On or after August 15, 2021: Redeemable at 100% of principal plus accrued interest.
- Change of Control: If a Change of Control occurs and the Notes are downgraded below investment grade by at least two rating agencies, the Company must offer to repurchase the Notes at 101% of principal plus accrued interest.
- Covenants: Limited negative covenants restrict incurring debt secured by liens on Principal Property and engaging in sale and lease-back transactions regarding Principal Property.
Outlook, Risks, and Contingencies
- Use of Proceeds: Proceeds are specifically earmarked to fund the acquisition of Caliper Life Sciences, Inc., pursuant to a Merger Agreement dated September 7, 2011.
- Default Risks: Events of default include payment defaults, covenant breaches, bankruptcy, insolvency, and failure to pay certain other indebtedness. Upon default, the entire principal may become immediately due.
- Rating Sensitivity: The repurchase obligation is contingent on a contemporaneous downgrade below investment grade following a Change of Control.
Investor Verification Checklist
- Verify the final closing of the $500 million Senior Notes offering and the actual net proceeds received.
- Confirm the status and expected closing date of the Caliper Life Sciences, Inc. acquisition.
- Review the full text of the Base Indenture (Exhibit 99.1) and Supplemental Indenture (Exhibit 99.2) for complete covenant details.
- Monitor credit rating actions by Moody's, S&P, and Fitch regarding the new Notes.
- Assess the impact of the new debt service obligations (5.00% interest) on the Company's future liquidity and leverage ratios.